Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Phase 2 Recruiting
257 enrolled
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Phase 3 Recruiting
364 enrolled
TroFuse-020
Phase 3 Recruiting
686 enrolled
ASPEN-09-03
Phase 2 Recruiting
120 enrolled
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Phase 3 Recruiting
1,100 enrolled
IMMUNOLIFE2
Phase 2 Recruiting
162 enrolled
CAMPFIRE
Phase 2 Recruiting
105 enrolled
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Phase 2 Recruiting
184 enrolled
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Phase 2 Recruiting
90 enrolled
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Phase 3 Recruiting
550 enrolled
FIL_A-BEGEV
Phase 1/2 Recruiting
122 enrolled
LUNG-05
Phase NA Recruiting
29 enrolled
ESMART
Phase 1/2 Recruiting
472 enrolled
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Phase 3 Recruiting
300 enrolled
AZALEA
Phase 2 Recruiting
45 enrolled
COMET
Phase 3 Recruiting
133 enrolled
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
Phase 3 Recruiting
192 enrolled
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Phase 3 Recruiting
376 enrolled
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Phase 3 Recruiting
400 enrolled
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Phase 2 Recruiting
135 enrolled
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Phase 3 Recruiting
200 enrolled
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Phase 3 Recruiting
378 enrolled
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Phase 2 Recruiting
71 enrolled
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
Phase 3 Recruiting
168 enrolled
ORIENTA
Phase 2 Recruiting
252 enrolled
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
Phase 3 Recruiting
632 enrolled
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase â…¡ Clinical Trial
Phase 2 Recruiting
240 enrolled
FaR-RMS
Phase 1/2 Recruiting
1,672 enrolled
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Phase 1/2 Recruiting
154 enrolled
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
Phase 3 Recruiting
302 enrolled